Eocene Ltd.
EOCNHealthcare|Medical - Pharmaceuticals|IL
$2.74
+0.29 (+11.84%)
About
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Stock Price
-33.2%(1Y)
1M
-24.3%
3M
-33.2%
6M
-33.2%
YTD
-33.2%
1Y
-33.2%
3Y
-33.2%
5Y
-33.2%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$2.9M
Employees6
CEOAllen J. Baharaff
IPO DateMar 12, 2014
Beta0.70
52-Week Range$2.3 – $12.32
Avg Volume26,441
ExchangeNASDAQ
Websitegalmedpharma.com
Ownership
Shares Outstanding1.0M
Data last updated: Nov 9, 2026, 04:09 AM